WESTBROOK, Maine, Jan. 12, 2024 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announced the expansion of its Fecal Dx® antigen testing platform ...
The launch of the Catalyst® Pancreatic Lipase Test demonstrates IDEXX's Technology for Life strategy and will provide veterinarians with quantitative results at the point-of-care in less than 10 ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the expansion of its Fecal Dx™ antigen testing platform with ...
IDEXX Laboratories is rated Hold, as its premium valuation already assumes strong recurring revenue and diagnostics growth.
Since launching in 2012, more than 50 million Fecal Dx antigen tests have been run worldwide,2 reflecting strong clinical adoption over time. With each menu expansion, Fecal Dx has grown into a ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results